Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

COVID-19 vaccination during pregnancy was not associated with major structural birth defects, according to a study published ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine ...